Participated · Series A · Aug 2025

Arnatar Therapeutics emerged from stealth to advance RNA-based therapeutics using its proprietary platforms, including the ACT-UP1 platform for upregulating protein expression and the DARGER™ platform that combines siRNA with upregulating ASOs. Its lead candidate, ART4, is an up‑regulating antisense oligonucleotide designed to increase endogenous JAG1 protein expression and is administered subcutaneously with once‑monthly dosing. In preclinical studies ART4 increased JAG1 protein levels, restored bile duct development, and reduced markers of liver injury (including bile acids and ALT) in a validated Alagille Syndrome mouse model; it was well tolerated in adult and newborn animals. The company plans to use its new funding to advance the DARGER™ platform and a pipeline targeting cardiometabolic, liver, CNS, and kidney diseases. Arnatar was founded in 2022, received seed financing from Apricot Capital, and is based in San Diego, CA.

Participated · Series A · Aug 2024

正序生物 is a genetic-disease immunotherapy platform that develops breakthrough therapies based on base editing. The company focuses on treatments for point-mutation–caused genetic diseases and cancer immunotherapy. Its pipeline includes CS-101 and in vivo gene‑editing therapy programs. The firm recently completed an A+ financing that will accelerate CS-101 clinical research and commercialization and support clinical translation of its in vivo therapy pipeline. The round also aims to fund global expansion and efforts to bring gene‑editing products to market. The financing exceeded RMB 100 million and involved multiple strategic and existing investors.

Participated · Equity · Jan 2024

Yilite Technology is a developer and manufacturer of high-performance liquid chromatography (HPLC) instruments and related accessories. Its product series span analytical, preparative and industrial-production chromatography systems, including high-pressure liquid pumps for chromatographic delivery. The company produces multiple types of detectors, autosamplers, metering pumps, chromatography workstations (including GPC/gel-permeation chromatography data processing), and a range of HPLC columns and accessories. Yilite has achieved product-series integration for complete liquid chromatography instrument systems. The article reports that the company recently completed its first-round financing of more than RMB 100 million. No revenue, user, founding-year, or location figures were disclosed in the article. Yilite Technology is a domestic company specializing in independent R&D and mass production of liquid chromatography products, holding a leading domestic market share in HPLC. The company has laid out over a hundred core patents and achieved a 95% domestication rate for chromatography equipment core components. Yilite reports cumulative domestic instrument sales exceeding 17,000 units and chromatography column sales over 200,000 units. Its product range covers HPLC across four models, UHPLC, LC‑MS/MS, GC, preparative chromatography from semi‑preparative to industrial scale, precision infusion devices, chromatography columns, and metering pumps. The company is extending into upstream purification for emerging biotechnologies and clinical analysis and diagnostics, and has launched clinical‑specific products such as hemoglobin A1c and blood drug concentration detection instruments. Yilite has begun building an overseas sales arm, reached strategic cooperation with well‑known overseas pharmaceutical customers, and by 2023 reported sales in 45 countries including the United States, Canada, the United Kingdom and Italy.

Participated · Series C · Sep 2023

Founded in 2018, Lingke Pharma (凌科药业) focuses on discovery and development of FIC/BIC therapies in autoimmune disease, inflammation and oncology. Its core programs center on second-generation highly selective and third-generation tissue-specific JAK inhibitors, with the small-molecule JAK1 candidate LNK01001 reporting positive Phase II data in rheumatoid arthritis, atopic dermatitis and ankylosing spondylitis showing strong efficacy and favorable safety. Multiple programs (including LNK01002 and LNK01003) have reported encouraging early clinical data, LNK01004 has enrolled its first patient in an Ib study for psoriasis and atopic dermatitis, and several assets are preparing to transition into Phase III. The company has submitted multiple end-of-Phase II / pre-Phase III meeting applications and says it will scale clinical development and invest in R&D teams and technology platforms. Frost & Sullivan is cited forecasting the JAK1 inhibitor market could reach USD 30.5 billion by 2030, underscoring the large market opportunity. Lingke says its innovation and clinical execution are being validated while it progresses toward broader late-stage development and eventual commercialization. Lynk Pharmaceuticals is a Hangzhou-based clinical-stage company focused on developing small-molecule FIC and BIC drugs for oncology and autoimmune diseases. Led by Dr. Zhao-Kui (ZK) Wan, Chairman and CEO, the core team has deep expertise in medicinal chemistry, biology, clinical and commercial development, with an average of more than 20 years in drug R&D. The company emphasizes innovation and differentiation, concentrating on highly selective second-generation and tissue-restricted third-generation JAK inhibitors while exploring novel targets. It currently has four Phase II clinical trials across four indications with promising clinical data. A few programs are expected to enter Phase III in the near future, and additional pipeline candidates have shown promising clinical and preclinical data with potential to become BIC/FIC drugs for several indications. The company intends to use the funds to accelerate the clinical development of its core products. Lynk Pharmaceuticals is a Hangzhou-based drug R&D company founded in 2018 and led by Chairman and CEO Dr. Zhao-Kui (ZK) Wan. It focuses on development of global FIC/BIC small-molecule drugs targeting autoimmune diseases, inflammation and cancers. In three and a half years since its establishment Lynk has obtained IND approvals for three original products in China and the United States and launched global clinical development. The company completed an ex-China out-license of LNK01001 and in-licensed a first-in-class RAS program from Kobe University and RIKEN in 2020. Lynk recently closed a $50M Series B to fund Phase I and II clinical trials for multiple programs and to support preclinical development of new projects. Management also plans to use proceeds to expand international business and strengthen collaborations with partner companies.

Led · Series B · Jun 2023

Eccogene is a clinical-stage biopharmaceutical company based in Shanghai focused on discovery and development of translational medicines for metabolic and immune-related diseases. Its pipeline targets metabolic indications including obesity, type 2 diabetes, NASH, and lipid disorders. Lead programs include ECC5004, a small-molecule GLP-1 receptor agonist for obesity and type 2 diabetes, and ECC4703, a THRβ full agonist for NASH and lipid disorders. The company also has ECC0509, a peripherally distributed SSAO/VAP-1 inhibitor, which is nearing completion of a Phase I clinical trial. Led by CEO Jingye Zhou, Eccogene intends to advance its clinical-stage metabolic pipeline using newly raised funds. The company positions itself to address unmet medical needs globally through translational medicine.